QuellTX Logo

News

PAGE:
1 2 3
27/04/22

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform

Collaboration combines Quell’s pioneering autologous multi-modular Treg cell therapy platform and Cellistic™’s expertise in iPSC cell therapy platform development and scale-upAims to accelerate the development of a next-generation allogeneic Treg platform that could open significant opportunities for Quell’s creation of…...

Read More
10/03/22

Quell Therapeutics Announces Presentation at Oppenheimer’s 32nd Annual Healthcare Conference

London, UK and Boston, MA, USA – March 10, 2022 – Quell Therapeutics Ltd (“Quell”), a world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...

Read More
06/01/22

Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

LONDON, UK and BOSTON, MA – January 6, 2022 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...

Read More
29/11/21

Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform

- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focused investors - Proceeds to be used…...

Read More
22/11/21

Quell Therapeutics Announces Participation in Upcoming Investor Conferences

London, UK and Boston, MA – November 22, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...

Read More
27/10/21

Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy

First clinical trial will investigate QEL-001 as a novel treatment to prevent organ rejection in liver transplant patients and eliminate the need for lifelong systemic immunosuppression London, UK and Boston, MA, USA – October 27, 2021 – Quell Therapeutics Ltd (“Quell”),…...

Read More
19/10/21

Quell Therapeutics Presents New Data Demonstrating the Ability of its Proprietary Phenotype Lock Technology to Enhance the Safety, Stability and Efficacy of Engineered Treg Therapies

Quell’s phenotype lock technology is a core element of its multi-modular engineered Treg platformLocks Treg cells in a potently suppressive phenotype and prevents switch to potentially pathogenic effector phenotypesPreclinical data presented at the European Society of Gene & Cell Therapy…...

Read More
23/09/21

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity  London, UK – September 23, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader…...

Read More
04/08/21

Quell Therapeutics to Present at the 2021 Wedbush Pacgrow Healthcare Virtual Conference

London, UK and Boston, MA, USA, August 4, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that Iain McGill, Chief Executive…...

Read More
PAGE:
1 2 3